Biodexa Pharmaceuticals Appoints Fiona Sharp as Chief Financial Officer and Director
BDRX is trading near its 52-week low of $2.22 (8.1% above the low).
Summary
Biodexa Pharmaceuticals Plc has appointed Fiona Sharp, previously Group Financial Controller, as its new Chief Financial Officer and a member of the Board of Directors, effective January 5, 2026.
Key Events · Executive and Board Changes · BDRX
-
New Chief Financial Officer Appointed
Fiona Sharp has been appointed as the Company's Chief Financial Officer and Corporate Secretary, effective January 5, 2026.
-
Joins Board of Directors
Ms. Sharp will also serve as a member of the Board of Directors.
-
Internal Promotion
Ms. Sharp previously served as Group Financial Controller of the Company since December 2019, indicating a seamless transition.
-
Leadership Restructuring
Stephen Stamp, who previously held the CFO and Corporate Secretary roles, will continue as Chief Executive Officer.
Analysis · BDRX · Life Sciences
Biodexa Pharmaceuticals Plc has strengthened its executive leadership by appointing Fiona Sharp as Chief Financial Officer and Corporate Secretary, who will also join the Board of Directors. Ms. Sharp's internal promotion from Group Financial Controller, a role she held since 2019, signals continuity and a smooth transition in financial oversight. This move is particularly important for a micro-cap company, as it solidifies financial governance and provides dedicated leadership for critical financial operations, while the former CFO, Stephen Stamp, remains as CEO.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1495 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.22 to $92.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.